July 22, 2013 7:20 AM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Raptor Pharmaceutical Corp.(Nasdaq: RPTP) today announced that it has received a positive opinion from theEuropean Union (EU) Committee for Orphan Medicinal Products (COMP)recommending orphan drug exclusivity for PROCYSBI^® (mercaptamine)gastro-resistant hard capsules for the treatment of proven nephropathiccystinosis. Final adoption of the opinions on drug approval and orphanexclusivity are expected from the European Commission in the coming months."The positive opinion from COMP is another welcome milestone for Raptor andPROCYSBI as we seek to bring this important new product to European patientswho suffer from cystinosis," said Christopher M. Starr, Ph.D., Raptor's chiefexecutive officer. "Orphan designation will provide the company with 10 yearsof marketing exclusivity in the European Union alongside our IP estate."The EMA's Orphan Drug Exclusivity is designed to provide regulatory andfinancial incentives for companies to develop and market therapies that treatlife-threatening or debilitating conditions with a prevalence in the EuropeanUnion (EU) of not more than five in 10,000. Orphan medicinal products receive10 years of market exclusivity in the EU after receiving marketingauthorization.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.